Lilly planning new Irish biopharma plant
pharmafile | December 15, 2011 | News story | Manufacturing and Production | lilly, manufactuing
Eli Lilly has filed a planning application to build a new 23,000 sq. m. biologics facility at its manufacturing site in County Cork, Ireland.
The three-story building marks another phase of investment in the biopharmaceutical-producing capacity of the site in Dunderrow, Kinsale, coming after a €400 million project to build a 158,000 sq. m. facility there started in 2008.
Construction of the biomanufacturing plant – which specialises in monoclonal antibodies – was completed in 2010 and it is due to come fully online next year.
One of the key products made there is Lilly’s solanezumab, an antibody designed to clear beta amyloid plaques from the brains of patients with Alzheimer’s disease, which analysts have tipped as a possible future blockbuster with multibillion dollar sales at peak. Phase III data on the drug are due in the first quarter of next year.
The planning application for the new facility is “in anticipation of a future increase in demand for the group’s biopharmaceutical products”, according to an Irish Times report, citing an unnamed company spokesperson.
Dunderrow has been run by Lilly since the early 1980s and is one of six bulk manufacturing plants operated by the company worldwide, making a range of products which are exported to fill-finish plants supplying worldwide markets.
Its main products are Zyprexa (olanzapine) for treatment of schizophrenia and Evista (raloxifene) for the prevention of osteoporosis.
In May, Lilly announced that 60-70 jobs would be lost at Dunderrow – mainly from voluntary redundancies – as part of a rationalisation of its worldwide manufacturing network. Around 460 staff currently work at the site.
Phil Taylor
Related Content
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …
Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …
Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …
